Tykerb (Bladder Cancer) - Analysis and Forecasts to 2020


#28407

24pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Tykerb (Bladder Cancer) Analysis and Forecasts to 2020 provides Tykerb global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Tykerb including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Tykerb including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2013-2020 for Tykerb

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Bladder Cancer Market 4
2.2 Bladder Cancer Disease 4
2.3 GlobalData Report Guidance 7

3 Baldder Cancer Disease: Market Characterization 8
3.1 Bladder Cancer Disease Market 8
3.2 Bladder Cancer Disease Market Forecasts and CAGR 9
3.3 Drivers for the Bladder Cancer Disease Market 9
3.3.1 High Prevalence 10
3.3.2 High Incidence 10
3.3.3 High Survival Rate 11
3.3.4 High lifetime costs 11

4 TNM Classification of bladder cancer 12
4.1 American Urological Association 12

5 Tykerb (Lapatinib) 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line reatment ofpatients with locally advanced or metastatic transitional cell carcinoma 15
5.3.2 A Phase II/III Randomised, Two-Arm, Comparison of Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with HER1 and/or HER-2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] 16
5.4 Approval History of Tykerb 16
5.5 Contraindications 16
5.6 Factors Impacting Sales 16
5.6.1 Bladder Cancer Market Characteristics 16
5.6.2 Mechanism of action 17
5.6.3 Niche market 17
5.6.4 Oral consumption 17
5.7 Drug risk benefit score(DRB) 17
5.7.1 Drug Efficacy 17
5.7.2 Drug Safety 18
5.7.3 Drug Compliance 18
5.7.4 Drug Dosing Convenience 18
5.8 Sales forecast 18
5.8.1 Target patient Pool of Tykerb 18
5.8.2Drug Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Tykerb 19

6 Bladder Cancer Market: Appendix 21
6.1 Market Definitions 21
6.2 List of Abberiviations 21
6.3 Research Methodology 21
6.3.1 Coverage 21
6.3.2 Secondary Research 21
6.3.3 Forecasting 22
6.3.4 Number of Patients Approved to take the Drug 22
6.3.5 Net Penetration of Drug 22
6.3.6 Net Annual Dosing 22
6.3.7 Annual Cost of Therapy 23
6.3.8 Primary Research 23
6.3.9 Expert Panels 23
6.4 Contact Us 23
6.5 Disclaimer 23
6.6 Sources 24

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030
Table 2: Five-Year Relative Survival Rates, 2005, By Stages
Table 3: Efficacy of Tykerb in Combination with Capacitabine vs Capacitabine Alone
Table 4: Efficacy of Tykerb in Combination with Letrozole vs Letrozole Alone
Table 5: Tykerb Approval History
Table 6: Drug Risk Benefit Score of Tykerb in Second-line treatment of Breast Cancer
Table 7: Annual Cost of Tykerb, Breast Cancer, 2011
Table 8: Tykerb, Breast Cancer, Global, Sales Forecasts ($m), 2007–2020
Table 9: Tykerb, Breast Cancer, The US, Sales Forecasts ($m), 2007–2020
Table 10: Tykerb, Breast Cancer, UK, Sales Forecasts ($m), 2008–2020
Table 11: Tykerb, Breast Cancer, France, Sales Forecasts ($m), 2008–2020
Table 12: Tykerb, Breast Cancer, Germany, Sales Forecasts ($m), 2008–2020
Table 13: Tykerb, Breast Cancer, Italy, Sales Forecasts ($m), 2008–2020
Table 14: Tykerb, Breast Cancer, Spain, Sales Forecasts ($m), 2008–2020
Table 15: Tykerb, Breast Cancer, Japan, Sales Forecasts ($m), 2009–2020


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage share of risk factors in Developed Countries 6
Figure 4: Percentage share of risk factors in Developing Countries 6
Figure 5: Smoking Consumption Curve, US,1960-2006 6
Figure 6: Bladder Cancer,Global, Market Size ($bn), 2009-2020 9
Figure 7: Oncology , Incidence, Worldwide ,2008-2030 10
Figure 8: Bladder Cancer, Incidence, Worldwide, 2008-2030 11
Figure 9: Broad Classification of Bladder Cancer 12
Figure 10: Classification of NMI Bladder Cancer 12
Figure 11: Detailed TNM Classifications 13
Figure 12: Classification of NMI Bladder Cancer 14
Figure 13: Tykerb Drug Model Diagram 19
Figure 14: Global Forecasted Sales of Tykerb for bladder cancer( $mn), 2013-2020 20